Interestingly, the slow-cycling cell phenotype, known to be a feature of a targeted therapy-resistant melanoma cells [28,106], can be prevented by the inhibition of p53, thus sensitizing melanoma cells to BRAFi/MEKi-targeted therapy [28]. Here, TP53 is linked to melanoma.